FMS vs DVA vs FXNC vs NKTR vs BAX

For growth investors, First National Corporation (FXNC) is the stronger pick with 27.

1% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate First National Corporation (FXNC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co.

KGaA (FMS) is the cheapest at 11. 0x versus DaVita Inc. at 20. 6x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1. 67x versus First National Corporation's 7. 87x — a reasonable growth-adjusted valuation.

Over the past 5 years, First National Corporation (FXNC) delivered a total return of +68.

7%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: FXNC returned +241. 1% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DaVita Inc.

(DVA) is the lower-risk stock at 0. 05β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 3799% more volatile than DVA relative to the S&P 500. On balance sheet safety, First National Corporation (FXNC) carries a lower debt/equity ratio of 23% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), First National Corporation (FXNC) is pulling ahead at 27.

1% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: First National Corporation grew EPS 96. 0% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, DVA leads at 5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

First National Corporation (FXNC) is the more profitable company, earning 15.

8% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FXNC leads at 19. 6% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1. 67x versus First National Corporation's 7. 87x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 13. 8x for DaVita Inc. — 4. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, BAX (3.

9% yield), FMS (3. 8% yield), FXNC (2. 2% yield) pay a dividend. DVA, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DaVita Inc.

(DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), +158. 1% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DVA: +158. 1%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FMS (Healthcare) and DVA (Healthcare) and FXNC (Financial Services) and NKTR (Healthcare) and BAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FMS is a mid-cap deep-value stock; DVA is a mid-cap quality compounder stock; FXNC is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; BAX is a small-cap income-oriented stock. FMS, FXNC, BAX pay a dividend while DVA, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.